A 62-year-male, hypertensive, had a 6-month history of painless, progressive bilateral (OU) lacrimal sac region swellings without epiphora. Examination revealed pea-sized swelling over the lacrimal sac regions OU (left eye \> right eye) \[[Fig. 1a](#F1){ref-type="fig"}\]. On syringing and irrigation, lacrimal system was freely patent. A detailed evaluation revealed inferior dystopia of the right eye (OD), and pinkish-red, lobulated, subconjunctival mass with vascularization was noted in the right superior and left inferior fornices \[[Fig. 1a](#F1){ref-type="fig"}\]. The rest of ophthalmic examination was normal. MRI orbits revealed similar soft-tissue lesions in both orbits, lacrimal sacs, and nasolacrimal ducts (NLD) \[[Fig. 1b](#F1){ref-type="fig"}\]. Lacrimal sac fine needle aspiration cytology (FNAC) \[[Fig. 1c](#F1){ref-type="fig"}\], and orbitotomy-incision biopsy \[[Fig. 1d](#F1){ref-type="fig"}\] suggested a low-grade non-Hodgkin\'s mucosa-associated lymphoid tissue (MALT) lymphoma (predominant CD20+).

![(a) Bilateral lacrimal sac region swellings (white arrows), right inferior dystopia, and left inferior orbital sulcus fullness. (b) MRI orbits (axial T2-weighted) shows bilateral lacrimal sac wall thickening (white arrows) and iso-intense orbital masses (arrowheads). (c) Cytology (10×) shows small round blue cells with coarse chromatin and scanty cytoplasm. (d) Sheets of round blue cells suggestive of lymphomatous malignancy (10×, H and E). (e) After chemotherapy, bilateral lacrimal sac regions and the right eye appears normal](IJO-68-554-g001){#F1}

What is Your Next Step? {#sec1-2}
=======================

Orbitotomy and excision biopsy + dacryocystorhinostomyOrbitotomy and excision biopsy + dacryocystectomySystemic workup + orbitotomy and mass excision + dacryocystorhinostomySystemic workup followed by chemotherapy ± radiotherapy.

Correct Answer: D {#sec1-3}
=================

Findings {#sec1-4}
========

The systemic workup revealed splenomegaly, enlarged para-aortic lymph nodes, and bone marrow infiltration with lymphomatous cells. Systemic chemotherapy was advised by the hemato-oncology department, including cyclophosphamide, doxorubicin, vincristine, and prednisolone. After the 6^th^ cycle, the patient showed complete resolution of both orbital and lacrimal sac region masses \[[Fig. 1e](#F1){ref-type="fig"}\]. Radiotherapy was deferred due to complete resolution post-chemotherapy. The patient was alive and disease-free locally, and systemically at 2 years follow-up recently.

Diagnosis {#sec1-5}
=========

Bilateral lacrimal sac and orbital non-Hodgkin\'s MALT lymphoma.

Discussion {#sec1-6}
==========

The MALT lymphomas are common among all lacrimal sac lymphomas (LSL).\[[@ref1]\] The diffuse large B-cell lymphoma behaves more aggressively, hence, have a poorer prognosis.\[[@ref1][@ref2]\] Among Japanese, 50% of LSL is of diffuse B-cell type while in western literature, the MALT lymphoma is reported to be more common (33%).\[[@ref2]\] The majority of LSL patients do not have epiphora due to the patent lumen of NLD as the lymphoma cells infiltrate the lacrimal drainage system associated lymphoid tissue (LDALT).\[[@ref1][@ref2][@ref3]\] The lack of prominent symptoms may lead to delayed presentation and diagnosis of LSL. MRI provides adequate information for orbital-adnexal lymphomas.\[[@ref1][@ref2][@ref3]\] Chemotherapy provides a successful outcome in terms of both local and systemic disease control.
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